Human epidermal growth factor receptor 2 (HER2) is over-expressed in a range of tumors including breast cancer, gastric cancer, lung cancer, and ovarian cancer, which has been extensively investigated in CAR-T therapy for solid tumors [9–11]. Here, ERBB2 is linked to breast cancer.